Adverse drug reactions and outcome of elderly patients on antituberculosis chemotherapy with and without XXXX .

@entity1 @entity3110 @entity5585 @entity3109 @entity1906 @entity1215
Antituberculosis (anti- @entity1906 ) chemotherapy with concomitant administration of @entity1215 and @entity3109 may cause a higher incidence of hepatotoxicity than @entity3109 alone. We carried out a prospective study of the adverse reactions to anti- @entity1906 drugs and the clinical outcome in elderly patients on anti- @entity1906 chemotherapy, to find out whether the omission of @entity1215 from standard anti- @entity1906 regime would result in a reduction of adverse reactions and/or mortality during anti- @entity1906 treatment. Eighty elderly @entity1 (age > 65 years) with @entity1906 were recruited into the study. They were randomised to receive anti- @entity1906 chemotherapy consisting of @entity3109 , @entity5585 and @entity3110 with or without @entity1215 for six months. Adverse reactions and mortality occurring during treatment were noted. A significantly higher number of @entity1 on @entity1215 had elevated liver enzymes compared with those not receiving @entity1215 . All of these reactions responded favorably to adjustment of anti- @entity1906 drugs. There was no significant difference between the two groups in the incidence of symptomatic adverse reactions or mortality during treatment. However, five @entity1 not given @entity1215 had unsatisfactory resolution radiographically and required additional therapy. We conclude that the inclusion of @entity1215 in the anti- @entity1906 regime offers a better therapeutic response but without significantly affecting the incidence of adverse reactions or mortality during treatment in elderly @entity1 with @entity1906 .
